Share

May 2021; 8 (3) EditorialOpen Access

The Calm Between Storms

Serum Biomarkers in Assessing Interattack Astrocytopathy in Neuromyelitis Optica Spectrum Disorder

Carolyn Goldschmidt, Robert A. Bermel
First published April 9, 2021, DOI: https://doi.org/10.1212/NXI.0000000000000988
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
490

Share

Article Information

vol. 8 no. 3 e988
DOI: 
https://doi.org/10.1212/NXI.0000000000000988
PubMed: 
33846269
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received February 1, 2021
  • Accepted in final form February 24, 2021
  • First Published April 9, 2021.
Copyright & Usage: 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Disclosures

    1. Carolyn Goldschmidt, DO (carolyngoldschmidt@gmail.com) and
    2. Robert A. Bermel, MD
  1. Carolyn Goldschmidt, DO (carolyngoldschmidt@gmail.com) and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National MS Society grant funding to support neuroimmunology fellowship

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Robert A. Bermel, MD
    3. Scientific Advisory Boards:

    1. Biogen, EMD Serono, Genentech, Genzyme, Novartis, VielaBio

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Biogen, Genzyme, Genentech, Novartis, Roche

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical procedures or imaging studies:

    1. Cleveland Clinic shares rights to intellectual property underlying the MSPT, currently licensed to Qr8 Health and Biogen.

    Research Support, Commercial Entities:

    1. Novartis, Genentech, Biogen

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. Robert Bermel shares rights to intellectual property underlying the MSPT, currently licensed to Qr8 Health and Biogen

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Mellen Center for MS Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio.
  1. Correspondence
    Dr. Bermel bermelr{at}ccf.org
View Full Text

Article usage

Article usage: April 2021 to August 2023

AbstractFullPdfSource
Apr 2021021751Highwire
May 2021024459Highwire
Jun 202119333Highwire
Jul 202114719Highwire
Aug 202112723Highwire
Sep 20210269Highwire
Oct 202103926Highwire
Nov 202112026Highwire
Dec 202112612Highwire
Jan 202201310Highwire
Feb 202211824Highwire
Mar 202213518Highwire
Apr 20220155Highwire
May 202201710Highwire
Jun 202201211Highwire
Jul 202202511Highwire
Aug 20220208Highwire
Sep 202202916Highwire
Oct 202203412Highwire
Nov 202214316Highwire
Dec 202221412Highwire
Jan 20232239Highwire
Feb 20231226Highwire
Mar 202331414Highwire
Apr 20231920Highwire
May 20231810Highwire
Jun 2023187Highwire
Jul 2023069Highwire
Aug 2023064Highwire

Cited By...

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me

Recommended articles